Saturday, January 21, 2017 3:17:02 PM
Plandaí is a research company headquartered in the Mpumalanga province of South Africa, approximately an hour west of the Kruger National Park in the northeast part of the country. Plandaí has the worldwide exclusive license to develop and market pharmaceutical applications for Phytofare® extracts, including the green-tea derived Catechin Complex that has been clinical proven to be 10-times more bioavailable than generics.
Green tea catechins have demonstrated a wealth of clinical health benefits and can be found in many different nutraceutical products, especially for weight loss. In laboratory, in vitro studies, catechins have shown remarkable potential for treating viruses, bacterial infections, inflammation, preventing certain cancers, and regulating blood sugar levels. However, like many botanical extracts, green tea has notoriously low bioavailability. Meaning, very little of what is consumed makes it intact to the blood stream. Phytofare®, with its superior bioavailability, can deliver all 8 catechins to the blood stream at therapeutic levels, where they remain active for over 24 hours.
What this means is that we have the potential, for the first time, to use an all-natural extract for pharmaceutical applications.
Commencing in early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in controlling blood sugar levels in diabetics. Mauritius has the highest per-capita incidence levels of diabetes in the world. Assuming the trials results are favorable, we anticipate having a product market-ready by Q4 2017 specific for managing insulin.
Future clinical trials will involve both the Catechin Complex and a citrus-based Limonoid Complex as we pursue treatments for inflammation, viruses (including malaria), soft-tissue injuries, and capillary integrity.
Source - Investors ~ Shareholder Update: http://www.protextm.co/investors/shareholder_update
Buy cautiously and sell reluctantly. All of my posts are In My Opinion only based on the DD I have completed. Please do your own DD and make your own decisions.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM